HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)

0 Saves · 2 Shares · 1 Comments Discussion

Grant Name

Funder

HHS-NIH11(National Institutes of Health)

Research Field

Health

Income Security and Social Services

Deadline

October 10, 2023 (Expired)

Grant Size

$15,000,000

Contact Info

National Institutes of Health FBOWebmaster@OD.NIH.GOV

Eligibility

Special district governments, Private institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, City or township governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), Public and State controlled institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, State governments, Public housing authorities/Indian housing authorities, Native American tribal governments (Federally recognized), For profit organizations other than small businesses, Small businesses, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), County governments, Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Grant Number

RFA-NS-21-015

Description

This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the proposal must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease. This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered.

Website

http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-015.html

Funding resources
NIH General Instructions	Download File
NIH Application Guide	Open Link
Purdue Grant Writing Lab: Introduction to Grant Writing	Open Link
University of Wisconsin Writing Center: Planning and Writing a Grant Proposal	Open Link